Phase 2 pumitamig PD‑L1×VEGF‑A bispecific antibody neoadjuvant platform in resectable NSCLC.
Trial status
Registered, Not Yet Recruiting
Status as of
Got an update?- Trial ID
- NCT07871214 on ClinicalTrials.gov
- Cancer type
- Non-Small Cell Lung Cancer (NSCLC)
- Stage of research
- Exploratory
- Location
- Global: US, Canada, Australia, China, Taiwan, South Korea, Japan, UK, and Europe
- Published in
- New in Oncology - Nov 12, 2026
ROSETTA Lung-220 is a Phase 2, randomized, open-label, multicenter, multi‑arm neoadjuvant platform study testing pumitamig-based regimens given before surgery to assess safety, tolerability, and whether patients can still proceed to planned resection on time. Pumitamig (also known as BNT327/BMS‑986545/PM8002) is a PD‑L1 and VEGF‑A–directed bispecific antibody designed to pair immune checkpoint blockade with anti‑angiogenic signaling inhibition in one molecule, and here it is combined with standard platinum doublet chemotherapy (e.g., cisplatin or carboplatin with pemetrexed or paclitaxel, depending on histology). The sponsor is Bristol Myers Squibb, with BioNTech listed as collaborator, positioning this as an important “partnered” immuno-oncology asset being pushed across multiple ROSETTA programs. Eligible participants are treatment‑naive patients with resectable stage IIA–IIIB NSCLC and evaluable PD‑L1 expression, a group where current care increasingly uses perioperative chemo‑immunotherapy (commonly nivolumab or pembrolizumab with platinum chemotherapy) followed by surgery and risk-adapted adjuvant therapy; this study asks whether adding VEGF‑A targeting via a bispecific can deepen pathologic responses without compromising surgical feasibility. The commercial/scientific angle is leveraging a single bispecific to deliver dual PD‑(L)1 + VEGF biology that previously required multi-drug combinations (e.g., checkpoint inhibitor plus bevacizumab), potentially simplifying development and differentiation if perioperative endpoints look strong.
More in non-small cell lung cancer
-
New trial · Nov 19, 2026 · NCT07756645
Phase 3 ABBV-1480 PD-1×VEGF bispecific antibody vs pembrolizumab in 1L sqNSCLC -
New trial · Nov 19, 2026 · NCT07393555
Phase 2 sacituzumab govitecan (TROP2 ADC) ± ivonescimab (PD-1×VEGF bispecific) in AGA+ NSCLC -
New trial · Nov 19, 2026 · NCT07899801
Phase 1a/1b zanidatamab (HER2 bispecific antibody) + zongertinib (HER2 TKI) in HER2-mutated NSCLC -
New trial · Nov 12, 2026 · NCT07874490
Phase 2 osimertinib EGFR inhibitor plus cyclosporine A calcineurin/NFAT inhibitor in EGFR-mutant NSCLC -
New trial · Nov 12, 2026 · NCT07864584
Phase 1/2 NHT102 inhaled azacitidine DNA hypomethylating agent (DNMT inhibitor) in NSCLC
